Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. Dr Munshi covers BCMA-targeting CAR T-cells, venetoclax, induction regimens and measurable reisdual disease monitoring.
Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD
